Navigation Links
Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
Date:9/14/2009

TARRYTOWN, N.Y., Sept. 14 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the completion of patient enrollment in two randomized, double-masked, Phase 3 clinical trials evaluating VEGF Trap-Eye in the treatment of the neovascular form of age-related macular degeneration (wet AMD). In each study of the VIEW (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD) program, VEGF Trap-Eye is being evaluated for its effect on maintaining and improving vision when dosed as an intravitreal injection on a schedule of 0.5 milligram (mg) every four weeks, 2.0 mg every four weeks, or 2.0 mg every eight weeks (following three monthly doses), as compared with intravitreal ranibizumab (Lucentis((R)), a registered trademark of Genentech, Inc.) administered 0.5 mg every four weeks during the first year of the studies. As-needed (PRN) dosing with both agents is being evaluated during the second year of each study. These studies are part of the global development program for VEGF Trap-Eye being conducted by Regeneron and Bayer HealthCare AG. Each study has enrolled in excess of the targeted 1,200 patient goal. One-year primary endpoint data from both studies are expected in the fourth quarter of 2010.

VEGF Trap-Eye, an investigational drug, is being developed by Regeneron and Bayer HealthCare AG for the potential treatment of eye diseases, including wet AMD, diabetic macular edema (DME), and Central Retinal Vein Occlusion (CRVO). Regeneron maintains exclusive rights to VEGF Trap-Eye in the United States. Bayer HealthCare has exclusive rights to market VEGF Trap-Eye outside the United States, where the companies will share equally in profits from any future sales of VEGF Trap-Eye.

"Even with recent advances in the treatment of wet
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
2. Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program
3. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
4. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
5. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
6. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
7. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
8. InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
9. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
10. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
11. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... 14, 2014 The Brandeis Medical Center, led by Dr. ... premier and affordable laser tattoo removal experience with the advanced Astanza ... in providing high quality cosmetic services with cutting edge medical technology ... Southern California has seen a dramatic increase in ...
(Date:1/14/2014)... 14, 2014 NineSigma , Inc., the leading ... Innovation Leadership Summit , May 14-16, 2014 at the ... Ohio . This is the ... to breakthrough achievements through open innovation. Participants will learn ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... , FORT LAUDERDALE, Fla., Dec. 22 LifeSync ... purchased the Besson Patent Portfolio and other wireless vital ... the use of wireless, two-way, digital communication between patient-electrodes ... patient. The acquired patent portfolio includes additional wireless improvements ...
... , HULL, England and FT. SASKATCHEWAN, Canada, ... & Nephew plc (LSE: SN; NYSE: SNN ), ... substantially all of the assets of Nucryst Pharmaceuticals Corp. ("Nucryst") ... manufacturing assets from Nucryst,s Fort Saskatchewan, Canada operations and the ...
Cached Medicine Technology:Smith & Nephew Completes Acquisition of the Assets of Nucryst Pharmaceuticals Corp. 2Smith & Nephew Completes Acquisition of the Assets of Nucryst Pharmaceuticals Corp. 3
(Date:4/24/2014)... It is better to give than to receive at ... new study suggests. , The study found that 15- and ... their money to family members, are less likely to become ... risks or keeping the money for themselves. , The researchers ... Academy of Sciences . , The study focused on the ...
(Date:4/24/2014)... National Science Foundation has awarded LSU Health Sciences ... (REU) Site grant in the amount of $295,635. ... from diverse social and educational backgrounds, underrepresented in ... The project will provide students with training ... It will be led by Principal Investigator ...
(Date:4/23/2014)... frozen stool from healthy, unrelated donors was safe ... diarrhea caused by Clostridium difficile , according ... Clinical Infectious Diseases and available online. Known ... effective whether given via a colonoscope or a ... make this promising treatment more readily available to ...
(Date:4/23/2014)... director at the National Institute of Arthritis and Musculoskeletal ... recipient of the Ross Prize in Molecular Medicine, conferred ... Medicine . The award will be given on June ... Manhattan, followed by scientific presentations by Dr. O,Shea and ... Institutes of Health. , The award, which includes a ...
(Date:4/23/2014)... have developed a way to detect and measure cancer ... particles with tails of synthetic DNA., A team led ... used gold nanoparticles to target and bind to fragments ... variants, which can indicate the presence and stage of ... in a cell can be determined by examining the ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... in the journal Annals of Neurology, says that radiation emitted ... is the first study to show that mobile phone affect ... ,Italian researchers found in the current study that ... brain closest to the phone when used for 45 minutes ...
... set of dietary guidelines. Apart from the dietary guidelines ... Dietary Guidelines, the revised Food Guide Pyramid and food ... ,All the guidelines though are given by different organizations ... by all are increased intake of fruit and vegetables, ...
... mosquito-transmitted viral fever//, has claimed two lives in Madhya ... officials said. ,The disease, which has been reported ... the state through villages in Betul district bordering Maharashtra, ... stooped posture to the victim as a result of ...
... symptom of Sj?gren’s (SHOW-grins) syndrome was found to be the ... periods. ,Typical signs and symptoms include dry, gritty ... causes difficulty swallowing, dental cavities and enlarged parotid glands. The ... and in front of your ears. Other signs and symptoms ...
... treatments has been accused of placing money before patients//, ... drug. <BR.,Patients suffering from cancer linked to asbestos will ... is pemetrexed disodium, after a study conducted ... ,The group analyzed the cost effectiveness of the ...
... is made easy but the new fat-busting laser treatment called SmartLipo. ... to be a quicker and less invasive form of liposuction//. It ... the double chins areas. About six cosmetic surgery clinics in ... treatment. ,But he Food and Drug Administration (FDA) has ...
Cached Medicine News:
Plastic micro-hematocrit capillary tubes from Globe Scientific Inc. are designed for use in 75 mm (3 inches) hematocrit centrifuges and come with many features....
Hemato-clad Hematocrit Tubes combine the precision of glass with the safety provided by a Mylar® overwrap. Now you can give your laboratory staff safety with no compromise in accuracy....
... Vivid 3 system is designed to address ... performance, and offer an even wider range ... the OR. From color flow imaging with ... new Vivid 3 offers a wealth of ...
... Volcano's new VH IVUS technology ... allow simplified interpretation of ultrasound images ... composition of each patient's atherosclerotic plaques. ... plaque component types: fibrous, fibro-fatty, dense ...
Medicine Products: